Example collocations logo

Diagnostic in sentence

201 examples of Diagnostic in a sentence

Better metrics would also become an important diagnostic tool, helping countries both identify problems before matters spiral out of control and select the right tools to address them.
Indeed, incorporating this principle into both fields could result in new diagnostic capabilities and new forms of individualized treatment, with a different therapy designed for each person.
Touring the Mwandama Village, I saw the potential of modern technologies – smart phones and mobile broadband, improved seed varieties, the latest in drip irrigation, modern diagnostic tests for malaria, and low-cost solar-energy grids – to advance human well-being in ways that simply were not feasible even a few years ago.
The worker used a low-cost diagnostic kit to confirm the malaria diagnosis, circumventing the need for a microscope and laboratory; a smart phone to key in the test results and receive advice from an “expert system” designed by public-health specialists; and state-of-the-art combination drug therapy to cure the illness.
According to the World Health Organization, the number of deaths from the disease has fallen by a staggering 60% since 2000 – the result of improved access to diagnostic testing and treatment.
At the World Economic Forum’s annual gathering in Davos last month, 85 companies, including vaccine developers, large pharmaceutical companies, diagnostic developers, and biotech firms, committed to further action to reduce drug resistance.
A natural niche for Japan would be technology developments in the service sector – such as the development of diagnostic instruments in the health-care industry.
Those opposed to such rampant use of drugs note that diagnostic rates for bipolar disorder, in particular, have skyrocketed by 4,000% and that overmedication is impossible without over-diagnosis.
The addition of even one new diagnostic code has serious practical consequences.
Indeed, the technology has led to the development of highly specific diagnostic tests; blockbuster anti-cancer drugs such as Rituxan (rituximab), Erbitux (cetuximab), and Herceptin (trastuzumab); and Avastin (bevacizumab), which is widely used to treat both cancer and diseases of the retina that commonly cause blindness.
Such findings unlock the possibility of a diagnostic test well before the disease manifests itself, and of developing drugs that prevent – or even reverse – the cancer’s development.
Taking advantage of it will require the rapid development and dissemination of effective diagnostic tools, novel drug treatments, and innovative vaccines, in conjunction with efforts to ensure that health-care systems are equipped to deliver the right care.
For starters, there is no fast point-of-care diagnostic test for TB.
In low-income countries, the dominant diagnostic method is sputum microscopy, an outdated approach that fails to detect TB in about half of all infected patients, with an even lower success rate for young children and patients co-infected with HIV.
But scaling up investment in diagnostic tools and treatments for TB costs more money than has been allocated.
And the right care requires rapid development and dissemination of new tools, including quick point-of-care diagnostic tests, safe and fast-acting drugs, and an effective TB vaccine.
But this is not the first case of damaging diagnostic overreach by the APA.
Ultimately health systems must be strengthened to enable health care providers to find TB that is present in communities with more sensitive and specific diagnostic tests, treat TB according to the class of the organism with the latest and most potent drugs, and prevent TB among those who are at risk.
To prevent superbugs from claiming an estimated ten million lives a year by 2050, we will need to invent new types of antimicrobial drugs and develop rapid diagnostic tests to avoid unnecessary treatment and cut our massive overuse of antibiotics.
The results are unambiguous: innovation has been accelerated, leading to better diagnostic tests (for the presence of, say, the BRCA genes related to breast cancer) at much lower costs.
The $20 billion prize could be divided among the companies that first produce appropriate new diagnostic technologies, vaccines, or antibiotics to address the World Health Organization’s 12 “priority pathogens.”
Although more needs to be done to strengthen R&D pipelines for new diagnostic tools and antibiotics to treat drug-resistant infections, similar attention must be devoted to vaccine discovery, development, and uptake.
Above all, effective leadership requires contextual intelligence and an intuitive diagnostic ability that helps a leader understand change, set objectives, and align strategies and tactics accordingly.
The key to addressing this problem is, as the declaration recognizes, to develop and improve access to rapid point-of-care diagnostic tools.
Improved diagnostic technologies are undoubtedly within the reach of the world’s top technology firms.
If governments, say, mandated that particular diagnostic tests must be conducted before antibiotics could be prescribed, companies would have the necessary incentive.
While the development of these metrics is in its early stages, the ultimate aim is to develop a practical diagnostic tool that would function as an “MRI” for national decision-makers to assess their countries’ resilience to global risks.
Most people are practical enough to see that when, say, they have to go to the hospital for tests, what matters is whether the right kind of diagnostic machine is there for them, not whether there is a better machine for others somewhere else.
The cost per treated case of providing this cheap drug alongside clinical visits and diagnostic tests is just $13-15, which means that we could reach 75% of the population in low- and middle-income countries for just $3.5 billion.
Now there are a number of diagnostic tests, akin to marketers’ rules of thumb, for certain conditions.
BackNext